Results 251 to 260 of about 20,520 (283)
Some of the next articles are maybe not open access.
Biochemical and Biophysical Research Communications, 1975
Abstract Chenodeoxycholic acid (300 mg + 14 C) was administered orally to a bile fistula patient receiving a constant infusion of { 3 H}mevalonic acid. Suppression of endogenous cholic and chenodeoxycholic acid synthesis occurred within 2 to 4 hours and continued for the next 10 hours; synthesis returned to the baseline level after 18 hours ...
L. Gregg Halloran +3 more
openaire +3 more sources
Abstract Chenodeoxycholic acid (300 mg + 14 C) was administered orally to a bile fistula patient receiving a constant infusion of { 3 H}mevalonic acid. Suppression of endogenous cholic and chenodeoxycholic acid synthesis occurred within 2 to 4 hours and continued for the next 10 hours; synthesis returned to the baseline level after 18 hours ...
L. Gregg Halloran +3 more
openaire +3 more sources
Chenodeoxycholic Acid: Uses and Limitations
Hospital Practice, 1979Conclusions about the efficacy and safety of this agent for dissolving cholesterol gallstones must wait until late next year, when results of large clinical trials are available. But results from many studies are available, as are preliminary clinical data from trials of a possible alternative, ursodeoxycholic acid.
openaire +3 more sources
Effect of dietary chenodeoxycholic acid and lithocholic acid in the rabbit [PDF]
The American Journal of Digestive Diseases, 1974 The feeding of chenodeoxycholic acid or lithocholic acid (0.05 or 0.5% of the diet) to rabbits produced cirrhotic and necrotic changes in the liver, accompanied by an increase of secondary bile acids in bile. Animals fed 0.05% lithocholic acid, 0.05% or 0.5% chenodeoxycholic acid, but not those receiving 0.5% lithocholic acid were able to survive for a
E. H. Mosbach +3 more
openaire +2 more sources
Gallstone dissolution with chenodeoxycholic acid [PDF]
Klinische Wochenschrift, 1980 Out of 95 patients with radiolucent gallstones who enrolled in a clinical study with chenodeoxycholic acid (CDC) for gallstone dissolution 75 patients with cholecystolithiasis completed 12 months of treatment. As a side effect 31% of patients reported intermittent diarrhea which did not cause cessation of therapy or missing of work.
K. H. Holtermüller +2 more
openaire +2 more sources
Chenodeoxycholic acid therapy in erythrohepatic protoporphyria
Journal of Hepatology, 1986The short-term effect of chenodeoxycholic acid administration on the excretion of protoporphyrin was investigated in 5 patients suffering from erythrohepatic protoporphyria. Faeces were collected for 7 days, 10 ml of bile was sampled daily and blood was drawn every 2 to 3 days.
J. Willem O. van den Berg +4 more
openaire +3 more sources
Dissolution of Cholesterol Gallstones by Chenodeoxycholic Acid
New England Journal of Medicine, 1972Abstract Seven women with gallstones were given 0.75 to 4.5 g per day of chenodeoxycholic acid, a primary bile acid, to promote micellar solubilization of cholesterol in bile. In Case 1 three stones that had remained unchanged in size during six years of observations disappeared after six months of treatment.
Johnson L. Thistle +3 more
openaire +3 more sources
Treatment of Gallstones with Chenodeoxycholic Acid and Phenobarbital
New England Journal of Medicine, 1975In a controlled trial, 36 patients with asymptomatic radiolucent gallstones were treated with chenodeoxycholic acid, 750 mg per day, phenobarbital, 180 mg per day, combination of both drugs, and placebo. After one year, chenodeoxycholic acid, phenobarbital and the combination, but not placebo, significantly decreased biliary cholesterol saturation. The
Leonard I. Goldstein +5 more
openaire +3 more sources
Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid
Annals of Neurology, 1985AbstractWe describe a patient with cerebrotendinous xanthomatosis who was treated for one year with chenodeoxycholic acid. Modest clinical improvement was accompanied by marked improvement in visual and brainstem auditory evoked potentials. Improved central nervous system function coincided with return of plasma and cerebrospinal fluid cholestanol ...
Carolyn L. Warner +4 more
openaire +3 more sources
Physical-chemical properties of chenodeoxycholic acid and ursodeoxycholic acid
Gastroenterologia Japonica, 1980It is now relatively well established that chenodexoycholic acid (CDCA) and ursodeoxycholic acid (UDCA), which are 7-OH epimer, are cholesterol gallstone dissolving agent. We investigated physical-chemical properties of CDCA and UDCA with respect to critical micellar concentration (CMC), micellar molecular weights (MMW) and solubilizing power of ...
Tetsuo Hisadome +3 more
openaire +3 more sources
Chenodeoxycholic Acid: The British Experience
Hospital Practice, 1974Clinical trials of CDCA as a medical alternative to cholecystectomy were suspended in Britain in 1973 after animal studies raised questions of the agent's potential hepatotoxicity. Individual patients are still being accepted for treatment, however, with the focus shifting to such questions as the minimal effective dose.
openaire +2 more sources